- Home
- HQL
as 05-20-2024 2:35pm EST
$.
-
$.
-.%
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 384.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 120.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | 11.56% | Dividend Payout Frequency: | Quarterly |
| EPS: | 0.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.34 - $14.37 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of abrdn Life Sciences Investors Shares of Beneficial Interest (HQL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Saba Capital Management, L.P. | HQL | 10% Owner | May 6 '24 | Buy | $13.62 | 10,713 | $145,911.06 | 3,079,443 | SEC Form 4 |
| Saba Capital Management, L.P. | HQL | 10% Owner | May 6 '24 | Buy | $13.76 | 50,161 | $690,215.36 | 3,129,604 | SEC Form 4 |
| Saba Capital Management, L.P. | HQL | 10% Owner | May 1 '24 | Buy | $13.02 | 252 | $3,281.04 | 3,042,456 | SEC Form 4 |
| Saba Capital Management, L.P. | HQL | 10% Owner | May 1 '24 | Buy | $13.46 | 26,274 | $353,648.04 | 3,068,730 | SEC Form 4 |
| Saba Capital Management, L.P. | HQL | 10% Owner | Apr 26 '24 | Buy | $13.00 | 120,304 | $1,563,952.00 | 3,025,602 | SEC Form 4 |
| Saba Capital Management, L.P. | HQL | 10% Owner | Apr 22 '24 | Buy | $12.88 | 2,022 | $26,043.36 | 2,738,992 | SEC Form 4 |
| Saba Capital Management, L.P. | HQL | 10% Owner | Apr 22 '24 | Buy | $13.15 | 48,203 | $633,869.45 | 2,787,195 | SEC Form 4 |
| Saba Capital Management, L.P. | HQL | 10% Owner | Apr 18 '24 | Buy | $12.80 | 81,738 | $1,046,246.40 | 2,694,511 | SEC Form 4 |
| Saba Capital Management, L.P. | HQL | 10% Owner | Apr 18 '24 | Buy | $12.84 | 42,459 | $545,173.56 | 2,736,970 | SEC Form 4 |
| Reit Todd | HQL | Director | Jan 2 '24 | Buy | $13.80 | 1,000 | $13,798.00 | 1,000 | SEC Form 4 |
| Maher Bill | HQL | Director | Dec 28 '23 | Buy | $13.57 | 1,000 | $13,570.00 | 1,000 | SEC Form 4 |
Latest abrdn Life Sciences Investors Shares of Beneficial Interest News
HQL Breaking Stock News: Dive into HQL Ticker-Specific Updates for Smart Investing
ACCESSWIRE
11 days ago
abrdn Life Sciences Investors (HQL) and abrdn Healthcare Investors (HQH) Announce an Additional 20% Increase in Distribution Rates Representing a 50% Increase Since January 2024
ACCESSWIRE
2 months ago
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
ACCESSWIRE
2 months ago
abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Healthcare Opportunities Fund (THQ), and abrdn World Healthcare Fund (THW) Announce Investment Team Update
ACCESSWIRE
3 months ago
abrdn Life Sciences Investors (HQL) and abrdn Healthcare Investors (HQH) Announce a 25% Increase in Distribution Rates and abrdn Healthcare Opportunities Fund (THQ) Announces a 60% Increase in Distribution Rate
Business Wire
4 months ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
4 months ago
ClearBridge MLP Funds Announce Proposed Mergers and Updates for Tender Offers
Zacks
4 months ago
Here's What Key Metrics Tell Us About Hilltop Holdings (HTH) Q4 Earnings
GlobeNewswire
4 months ago